lutéine

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• age-related cognitive decline [Insufficient Evidence]
• age-related macular degeneration [Possibly Effective]
• Alzheimer dz [Insufficient Evidence]
• amyotrophic lateral sclerosis [Insufficient Evidence]
• asthenopia (eye strain) [Insufficient Evidence]
• asthma [Insufficient Evidence]
• bronchopulmonary dysplasia [Possibly Ineffective]
• cancer prevention, cervical [Insufficient Evidence]
• cancer prevention, colorectal [Insufficient Evidence]
• cancer prevention, esophageal [Insufficient Evidence]
• cancer prevention, gastric [Insufficient Evidence]
• cancer prevention, lung [Insufficient Evidence]
• cancer prevention, pancreatic [Insufficient Evidence]
• cardiovascular dz prevention [Insufficient Evidence]
• cataracts [Possibly Effective]
• central serous retinopathy [Insufficient Evidence]
• child development [Insufficient Evidence]
• choroideremia [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes [Insufficient Evidence]
• diabetic retinopathy [Insufficient Evidence]
• exercise-induced muscle soreness [Insufficient Evidence]
• fracture [Insufficient Evidence]
• glaucoma [Insufficient Evidence]
• hyperlipidemia [Insufficient Evidence]
• infertility [Insufficient Evidence]
• macular telangiectasia type 2 [Insufficient Evidence]
• metabolic syndrome [Insufficient Evidence]
• myopia [Insufficient Evidence]
• necrotizing enterocolitis prevention [Possibly Ineffective]
• non-Hodgkin lymphoma [Insufficient Evidence]
• obesity [Insufficient Evidence]
• Parkinson dz [Insufficient Evidence]
• pre-eclampsia [Insufficient Evidence]
• respiratory infections [Insufficient Evidence]
• retinitis pigmentosa [Possibly Ineffective]
• retinopathy of prematurity [Possibly Ineffective]
• ulcerative colitis [Insufficient Evidence]
• visual development [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

age-related cognitive decline

[Insufficient Evidence]

Dose: 10-12 mg PO qd

age-related macular degeneration

[Possibly Effective]

Dose: 5-20 mg PO qd

Alzheimer dz

[Insufficient Evidence]

Dose: 10 mg PO qd

asthenopia (eye strain)

[Insufficient Evidence]

Dose: 17.5 mg PO qd; Info: used w/ omega-3 fatty acids and bilberry

cataracts

[Possibly Effective]

Dose: 6-11.7 mg PO qd; Alt: 15 mg PO 3x/wk

cognitive function

[Insufficient Evidence]

Dose: 10 mg PO qd; Info: given w/ high fat meal

glaucoma

[Insufficient Evidence]

Dose: 10 mg PO qd

macular telangiectasia type 2

[Insufficient Evidence]

Dose: 10 mg PO qd

non-Hodgkin lymphoma

[Insufficient Evidence]

Dose: up to 20 mg PO qd

obesity

[Insufficient Evidence]

Dose: 20 mg PO qd